Keymed Biosciences Inc. Stock
Stocks
2162
KYG5252B1023
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.85 HKD | +6.76% |
|
+35.60% | +62.49% |
| 06-05 | Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close | MT |
| 06-04 | Lakefront Biotherapeutics, Gilead Complete Ouro Acquisition for $1.68 Billion Upfront | MT |
| Market Cap | 22.17B 25.62B 3.27B 2.85B 2.62B 2.43B 4.63B 312B 4.7B 31.37B 12.21B 153B 12.27B 12B 529B | P/E 2026 * |
43.5x | P/E 2027 * | 204x |
|---|---|---|---|---|---|
| Enterprise Value | 21.36B 24.69B 3.15B 2.75B 2.53B 2.35B 4.46B 300B 4.52B 30.23B 11.77B 147B 11.82B 11.56B 510B | EV / Sales 2026 * |
8.88x | EV / Sales 2027 * | 9.71x |
| Free-Float |
70.26% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +6.76% | ||
| 1 week | +35.60% | ||
| Current month | +22.76% | ||
| 1 month | +48.72% | ||
| 3 months | +21.72% | ||
| 6 months | +54.81% | ||
| Current year | +62.49% |
| 1 week | 70 |  | 89.7 |
| 1 month | 52.6 | | 89.7 |
| Current year | 44.66 | | 89.7 |
| 1 year | 44.45 | | 89.7 |
| 3 years | 26.6 | | 89.7 |
| 5 years | 16.9 | | 89.7 |
| 10 years | 16.9 | | 89.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bo Chen
CEO | Chief Executive Officer | 52 | 2018-04-22 |
Changyu Wang
PRN | Corporate Officer/Principal | 61 | 2021-03-02 |
Qian Jia
PRN | Corporate Officer/Principal | 61 | 2018-02-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Cheuk Kin Law
BRD | Director/Board Member | 63 | 2021-06-30 |
Yang Ke
BRD | Director/Board Member | 71 | 2021-04-02 |
Bo Chen
CHM | Chairman | 52 | 2018-04-22 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-06-12 | Moonshot Holdings Ltd.
| Other | Company | 21,600,000 | 7.7216% | |
| 25-06-10 | Moonshot Holdings Ltd.
| Other | Company | 18,800,000 | 6.7206% | |
| 23-09-14 | Moonshot Holdings Ltd.
| Other | Company | 114,500 | 0.0409% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.76% | +35.60% | +89.63% | +92.15% | 3.06B | |
| -2.14% | +3.65% | +74.05% | +131.89% | 59.1B | |
| -0.93% | +4.05% | +73.64% | +90.53% | 55.19B | |
| -3.71% | +2.97% | -14.61% | -13.89% | 24.67B | |
| -0.05% | +7.89% | +14.05% | +440.15% | 24.19B | |
| +0.64% | +14.41% | +44.27% | -3.20% | 19.69B | |
| -2.19% | +7.37% | +40.74% | -30.67% | 17.56B | |
| +3.58% | +25.11% | +196.41% | +363.46% | 16.22B | |
| +4.91% | +25.24% | +44.61% | - | 14.84B | |
| -0.57% | +1.39% | +20.33% | +191.65% | 14.04B | |
| Average | +0.63% | +10.25% | +58.31% | +140.23% | 24.85B | |
| Weighted average by Cap. | -0.61% | +6.68% | +57.99% | +134.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.41B 2.78B 355M 309M 285M 264M 503M 33.81B 510M 3.4B 1.33B 16.56B 1.33B 1.3B 57.44B | 2.16B 2.49B 318M 277M 255M 237M 451M 30.3B 457M 3.05B 1.19B 14.84B 1.19B 1.17B 51.48B |
| Net income | 295M 342M 43.55M 37.98M 34.98M 32.45M 61.75M 4.15B 62.59M 418M 163M 2.03B 164M 160M 7.06B | 44.14M 51.01M 6.5M 5.67M 5.23M 4.85M 9.22M 620M 9.35M 62.46M 24.32M 304M 24.43M 23.89M 1.05B |
| Net Debt | -804M -930M -119M -103M -95.23M -88.35M -168M -11.31B -170M -1.14B -443M -5.54B -445M -435M -19.21B | -1.23B -1.42B -181M -158M -145M -135M -257M -17.28B -260M -1.74B -677M -8.46B -680M -665M -29.35B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-06 | HK$86.85 | +6.76% | 7,635,277 |
| 26-07-03 | HK$81.35 | +8.54% | 4,503,635 |
| 26-07-02 | HK$74.95 | +5.94% | 5,840,251 |
| 26-06-30 | HK$70.75 | -3.21% | 4,035,414 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2162 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
